Morelli, Eugenio
Hunter, Zachary R.
Fulciniti, Mariateresa
Gullà, Annamaria
Perrotta, Ida Daniela
Zuccalà, Valeria
Federico, Cinzia
Juli, Giada
Manzoni, Martina
Ronchetti, Domenica
Romeo, Enrica
Gallo Cantafio, Maria Eugenia
Soncini, Debora
Maltese, Lorenza
Rossi, Marco
Roccaro, Aldo M.
Cea, Michele
Tassone, Pierfrancesco
Neri, Antonino
Treon, Steven C.
Munshi, Nikhil C.
Viglietto, Giuseppe
Amodio, Nicola
Funding for this research was provided by:
Leukemia and Lymphoma Society
AMERICAN SOCIETY OF HEMATOLOGY
International Myeloma Foundation
National Cancer Institute (SPORE-P50CA100707, CA155258-10)
European Hematology Association
AIRC
Associazione Italiana per la Ricerca sul Cancro (IG-21588, IG24365, IG24449)
U.S. Department of Veterans Affairs (BX001584-09)
Article History
Received: 21 July 2022
Accepted: 30 August 2022
First Online: 12 September 2022
Declarations
:
: Patient samples were collected following informed consent approved by our Institutional Review Board at the Dana-Farber Cancer Institute. Animal studies were performed after approval by the Animal Ethics Committee of the DFCI and performed using institutional guidelines.
: All authors have read and approved the final manuscript.
: N.C.M. serves on advisory boards or is a consultant to Takeda, BMS, Celgene, Janssen, Amgen, AbbVie, Oncopep, Karyopharm, Adaptive Biotechnology, and Novartis and holds equity ownership in Oncopep. A.M.R. serves on advisory board of Amgen, Celgene, Janssen, and Takeda. No potential conflicts of interest were disclosed by the other authors.